Academics

Academics

Phone Number

Clinical Research
(803) 935-8300
Institutional Review Board
(803) 935-8300
Nursing Education
(803) 935-8504
Professional Training
(803) 936-7215
Graduate Medical Education Family Medicine
(803) 314-5494s
Graduate Medical Education Transitional Year
(803) 791-2769

Cancer Research

Working Toward a Cure

Our researchers contribute to the South Carolina Central Cancer Registry and have partnered with the MUSC Hollings Cancer Center to stay up-to-date on the latest clinical trials and treatments.

Current Trials

Bladder Cancer

Back to Top

Cysview

Description

The purpose of the study is to gather more information on the current use of Blue Light Cystoscopy™ with Cysview® in urologists' practices. This trial is a registry study for patients with bladder cancer who undergo cystoscopy. Cysview is an FDA approved drug imaging agent that is absorbed by malignant cells causing them to appear pink under blue light thus making them easier to see.

Open to enrollment

Posted By: Dr. T. Brian Willard

Posted Date: 5/20/2022

Location: Lexington Urology

Breast Cancer

Back to Top

NRG-CC011

Description
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Double-Blinded Controlled Trial.

A study to examine computerized training to improve concentration, learning new things, and remembering in breast cancer survivors. 

Open to enrollment. 

Posted By: Dr. Steven Madden

Posted Date: 5/23/2024

Location: Lexington Medical Cancer Center

NRG-BR008 HERO

Description
A Phase III Randomized Trial of Radiotherapy Optimization for low-risk HER2-Positive Breast Cancer.

This trial compares the recurrence-free interval (RFI) among patients with early stage, low-risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the current standard of care. 

Open to enrollment.

Posted By: Dr. Quillin Davis

Posted Date: 4/12/2024

Location: Lexington Medical Cancer Center

S2212 SCARLET

Description
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

This phase III trial compares the effects of shorter chemotherapy-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Open to enrollment.

Posted By: Dr. Steven Madden

Posted Date: 8/28/2023

Location: Lexington Medical Cancer Center

A012103

Description
Pembrolizumab vs. observation in people with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab.

Open to enrollment. 

Posted By: Dr. Steven Madden

Posted Date: 7/28/2023

Location: Lexington Medical Cancer Center

A212102

Description
Blinded Reference Set for Multicancer Early Detection Blood Tests. In this study, blood samples will be collected from patients with and without cancer to evaluate tests for early cancer detection.

Open to enrollment.

Posted By: Dr. James Wells

Posted Date: 6/23/2023

Location: Lexington Medical Cancer Center

A011801

Description
The Compassher2 Trials (Comprehensive Use Of Pathologic Response Assessment To Optimize Therapy In Her2-Positive Breast Cancer): Compassher2 Residual Disease (Rd), A Double-Blinded, Phase Iii Randomized Trial Of T-Dm1 And Placebo Compared With T-Dm1 And Tucatinib.

This trial studies how well trastuzumab emtanzine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. Giving T-DMI and tucatinib together may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. 

Open to enrollment 

Posted By: Dr. Steven Madden

Posted Date: 9/27/2019

Location: Lexington Medical Cancer Center

MA.39 Tailor RT

Description
This study tests regional radiation therapy in patients with low risk breast cancer.

Posted By: Dr. Davis

Posted Date: 9/5/2019

Location: Lexington Medical Cancer Center

Gastrointestinal Cancer

Back to Top

Head & Neck Cancer

Back to Top

Lung Cancer

Back to Top

NRG-LU008

Description
NRG-LU008: Phase III Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer.

This study is testing the addition of high dose, targeted radiation to the usual treatment for locally advanced inoperable non-small cell lung cancer. 

Open to enrollment.

Posted By: Dr. Quillin Davis

Posted Date: 7/29/2024

Location: Lexington Medical Cancer Center

Alchemist - A081801

Description
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer

Open to enrollment 

Posted By: Dr. James Wells

Posted Date: 11/23/2020

Location: Lexington Oncology

Prostate Cancer

Back to Top

BRAT

Description
The purpose of the Prostate BRAchyTherapy (BRAT) Registry is to measure clinical outcomes of patients treated with Brachytherapy at Lexington Medical Center (LMC).

Open to enrollment

Posted By: Dr. Quillin Davis

Posted Date: 11/1/2021

Location: Lexington Medical Cancer Center

EA8184

Description
To Evaluate if Green Tea can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring.

This study is being done to answer the following question:  Can we lower the chance of your prostate cancer growing by adding Sunphenon® 90D (containing green tea catechins) by closely monitoring your prostate cancer?

Open to enrollment

Posted By: Dr. T. Brian Willard

Posted Date: 11/1/2021

Location: Lexington Urology